Enliven Therapeutics Rallyes on Phase 1 ELVN-001 Data, FDA Confirms Phase 3 Dose
Enliven Therapeutics shares jumped nearly 19.9% in morning trading after the company presented updated Phase 1 data for ELVN-001 at EHA 2026. Trial results in the 80 mg once-daily Phase 1b cohort showed a 61% overall major molecular response rate, with the FDA agreeing that 80 mg once daily is the recommended Phase 3 dose and the ENABLE-2 pivotal t…